Last update June 10, 2018

Dobésilate de Calcium

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

A drug to which the ability to reduce capillary permeability is attributed. Used to treat diabetic retinopathy and hemorrhoids.
Administered orally in two daily doses.

Since the last update we have not found published data on its excretion in breastmilk, although the manufacturer indicates negligible excretion in breastmilk (OMPharma 2018, AEMPS 2017).

As there is less published information than for other drugs from the same group, safer known alternatives may be preferable during the neonatal period and in case of prematurity.


Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Dobésilate de Calcium is Calcium Dobesilate in French.

Is written in other languages:


Dobésilate de Calcium belongs to this group or family:


Main tradenames from several countries containing Dobésilate de Calcium in its composition:


Variable Value Unit
Oral Bioavail. 80 %
Molecular weight 418 daltons
Protein Binding 20 - 25 %
Tmax 4 - 6 hours
1 - 3 hours
Theoretical Dose 0.06 mg/Kg/d
Relative Dose 0.24 %


  1. OM Pharma. Dobesilate. Drug Summary. 2018 Full text (in our servers)
  2. AEMPS. Dobesilato. Ficha técnica. 2017 Full text (in our servers)
  3. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, Capellà D, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016 Abstract
  4. DGF. Dirección General de Farmacia. Servicio Canario de la Salud. Listado de fármacos considerados de Utilidad terapéutica Baja (UTB). None 2011 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM